Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck KGaA
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck
To assess whether overall survival time in subjects receiving cetuximab in combination with cisplatin or carboplatin + 5-FU is prolonged compared to subjects receiving cisplatin or carboplatin + 5-FU ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Randomized Phase II open-label controlled study of EMD 72000 (matuzumab) in combination with the chemotherapy regimen ECX or the chemotherapy regimen ECX alone as first-line treatment in subjects with metastatic esophago-gastric adenocarcinoma
The primary objective of this study is to determine the response rates of matuzumab in combination with ECX as background chemotherapy and of ECX alone in subjects with metastatic esophago-gastric can...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator
The primary objective of this trial is to demonstrate the effect of ONO 4641 versus IFN ? 1a (Avonex) 30 µg on the proportion of subjects, with RMS, who remain qualifying relapse?free during their par...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Long-term safety and tolerability study of atacicept in patients with Systemic Lupus Erythematosus who completed protocol EMR-700461-023 (ADDRESS II)
Determine the long-term safety and tolerability of atacicept in SLE subjects.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany
Update Il y a 4 ans
A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis
The primary objective of the study is to evaluate the effect of Rebif New Formulation 44 mcg (tiw and ow) versus placebo on the time to conversion to McDonald MS in patients with a first clinical demy...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Merck KGaA
Update Il y a 4 ans
Trial of pimasertib with SAR245409 or placebo in ovarian cancer
Evaluation of the objective tumor response of the combination therapy with pimasertib plus SAR245409 and of pimasertib plus SAR245409 placebo in subjects with previously treated unresectable low-gra...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Open, randomized, controlled, multicenter phase III study comparing 5-FU/FA plus irinotecan plus cetuximab versus 5-FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer
To assess whether the progression-free survival time under 5-FU/FA plus irinotecan plus cetuximab is longer than that under 5-FU/FA plus irinotecan as first-line treatment for epidermal growth factor ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
A Phase II Study of M2951 in SLE
- To evaluate the efficacy and dose response of M2951 compared to placebo in reducing disease activity in adult subjects with active, autoantibody-positive SLE who are receiving SoC therapy based on S...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Cilengitide (EMD121974) and temozolomide with concomitant radiation therapy, followed by cilengitide and temozolomide maintenance therapy in subjects with newly diagnosed glioblastoma multiforme – a multicenter, open-label, uncontrolled Phase I/IIa study
The primary objective of this exploratory study is to estimate the percentage of subjects who survived 6 months without disease progression (6-month PFS).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Sym004 versus Standard of Care in metastatic colorectal cancer Sym004 versus tratamiento estándar en cáncer colorectal metastásico
To assess the efficacy of 2 different weekly dosing regimens (9 mg/kg loading dose followed by 6 mg/kg/week dose versus 12 mg/kg/week) of Sym004 compared with investigator`s choice in terms of overall...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
Next